Well Referenced

Tag: GLP-1 receptor agonist

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

The 2023 OASIS 1 trial evaluated the efficacy and safety of oral semaglutide 50 mg daily in 667 adults with overweight or obesity without type 2 diabetes. Over 68 weeks, participants receiving semaglutide experienced a mean weight loss of 15.1%, compared to 2.4% with placebo. Notably, 85% of the semaglutide

Read More »
June 26, 2025 No Comments

Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial

This 2024 secondary analysis of a randomized clinical trial examined the effects of exercise, GLP-1 receptor agonist (liraglutide) treatment, and their combination on bone health in adults with obesity. After an initial 8-week low-calorie diet, 195 participants were randomized into four groups: exercise alone, liraglutide alone, combination of both, or

Read More »
June 26, 2025 No Comments

Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review

This 2022 mini-review discusses tirzepatide, a first-in-class dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, approved for type 2 diabetes and obesity management. Tirzepatide significantly reduces glycemic levels, improves insulin sensitivity, and promotes weight loss exceeding 20%, along with favorable effects on lipid metabolism. Its design

Read More »
June 26, 2025 No Comments

Tirzepatide Once Weekly for the Treatment of Obesity

This 2022 randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) over 72 weeks in 2,539 adults with obesity or overweight with at least one weight-related comorbidity, excluding diabetes. Participants receiving tirzepatide experienced significant, dose-dependent weight reductions: −15.0% with

Read More »
June 26, 2025 No Comments

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin

This 12-week open-label, prospective study evaluated the efficacy of combining liraglutide (1.2 mg/day subcutaneously) with metformin (1000 mg twice daily) in 40 obese, non-diabetic women with PCOS who had previously lost less than 5% body weight on metformin monotherapy. Participants were randomized into three groups: metformin alone (MET), liraglutide alone

Read More »
June 26, 2025 No Comments

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

This 2-year randomized, double-blind, placebo-controlled trial assessed the long-term safety, tolerability, and efficacy of once-daily subcutaneous liraglutide (1.2–3.0 mg) in 564 obese adults (BMI 30–40 kg/m²) across 19 European centers. After a 20-week core phase, 398 participants entered a 2-year extension. At 1 year, those on liraglutide 3.0 mg lost

Read More »
June 26, 2025 No Comments

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

This 56-week, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of 3.0 mg liraglutide in 3,731 overweight or obese adults without type 2 diabetes. Participants received daily subcutaneous injections of liraglutide or placebo, alongside lifestyle counseling. At week 56, the liraglutide group achieved a mean weight loss of 8.4

Read More »
June 26, 2025 No Comments